Methods of Treating Fibromyalgia With Psilocybin Compositions - Tryp Therapeutics
Summary
Tryp Therapeutics Inc. filed patent application US20260108545A1 with the USPTO on September 11, 2023 (application no. 19110772), published April 23, 2026. The application covers methods for treating fibromyalgia using psychedelics such as psilocybin or metabolites thereof, optionally combined with psychotherapy, with patient outcomes assessed through observer-rated and subject-reported measures as well as biological and clinical indicators. The inventors are James GILLIGAN and Peter GUZZO. Pharmaceutical and biotech companies pursuing psychedelic-based therapeutic research should monitor this filing as it may affect competitive patent positioning in fibromyalgia treatment.
“Provided are methods for treating fibromyalgia or one or more symptoms thereof, that involve the administration of psychedelics, such as psilocybin or a metabolite thereof, and related uses of the psychedelics.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 203 changes logged to date.
What changed
Tryp Therapeutics Inc. has filed patent application US20260108545A1 covering methods of treating fibromyalgia and associated symptoms through administration of psychedelics, specifically psilocybin or metabolites thereof, with optional psychotherapy and patient outcome assessments. The application includes methods for identifying subjects suitable for treatment and various assessment indicators including observer-rated, subject-reported, biological, and clinical measures.
For pharmaceutical and biotech companies developing psychedelic-based therapeutics, this patent filing represents potential prior art that could affect freedom-to-operate considerations in fibromyalgia treatment development. If granted, the patent would provide Tryp Therapeutics with exclusivity claims over specific treatment methods combining psilocybin administration with fibromyalgia symptom management approaches.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of treating fibromyalgia with compositions comprising psilocybin
Application US20260108545A1 Kind: A1 Apr 23, 2026
Assignee
Tryp Therapeutics Inc.
Inventors
James GILLIGAN, Peter GUZZO
Abstract
Provided are methods for treating fibromyalgia or one or more symptoms thereof, that involve the administration of psychedelics, such as psilocybin or a metabolite thereof, and related uses of the psychedelics. The disclosure in some aspects also relates to methods for identifying subjects for treatment of fibromyalgia with administration of psychedelics. In some aspects, the treatment also involves psychotherapy. In some aspects, the subject receiving the treatment is assessed for various indicators, such as observer-rated and subject-reported outcomes, biological and clinical indicators, and combinations thereof.
CPC Classifications
A61K 31/675 A61B 5/0245 A61B 5/055 A61B 5/369 A61B 5/4809 A61B 5/4815 A61B 5/4827 A61B 5/4848 A61K 9/0053 A61P 25/04 G01R 33/4806
Filing Date
2023-09-11
Application No.
19110772
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.